Case 01 · Asset diligence
European mid-cap pharma — GLP-1 in-licensing decision
The question
Should the corporate-development team in-license an early-stage oral GLP-1 mechanism, or partner for a late-stage monthly injectable?
What we did
Built a probability-adjusted commercial NPV comparison across both options, stress-tested against SURMOUNT-5 data, the Medicare GLP-1 Bridge demonstration, and three persistence scenarios. Mapped sterile fill-finish capacity for the late-stage option.
The outcome
Recommendation: pass on the early-stage oral, pursue partnership on the late-stage monthly. Saved the client an estimated 18 months of opportunity cost.
Case 02 · Competitive landscape brief
US biotech investor — sector positioning paper
The question
What does the 2030 incretin market look like under bear, base, and bull cases, and which mid-cap names are mispriced against the scenario tree?
What we did
Triangulated JPMorgan, Goldman Sachs, Morgan Stanley, EvaluatePharma, IQVIA, and BMO forecasts. Built sponsor-by-sponsor revenue waterfalls under each hinge variable.
The outcome
Two-page IC memo + 12-slide deck supporting the investor’s LP communication for Q1 2026. Underlying brief refreshed quarterly.
Case 03 · Market entry strategy
EU specialty biotech — UK / Ireland launch sequencing
The question
For a novel-mechanism cardiometabolic asset, should the launch sequence prioritise NHS England (post-NICE) or wait for HSE Ireland reimbursement parity?
What we did
Built a country-by-country HTA scenario, payer archetype mapping, and sales-force sizing logic. Stress-tested NICE TA1026-style commissioning timelines against the HSE reimbursement target.
The outcome
Decision to launch UK first, build Irish KOL coverage in parallel, formal HSE submission Q4 2026. Net result: launch-economics IRR moved 220 bps.
Case 04 · Board briefing
Irish pharma services provider — strategic board pre-read
The question
Following Novo Holdings’ acquisition of Catalent, how does the fill-finish landscape in Europe reshape contract-manufacturing pricing power?
What we did
Two-page principal memo with explicit recommendations, plus a 10-slide pre-read deck for the board meeting and a 30-minute live Q&A with the analyst.
The outcome
Board approved capex acceleration on a second sterile-fill line. Memo informed the subsequent Series A pitch deck for a related joint venture.
Case 05 · Pipeline intelligence
US asset manager — cardiometabolic retainer
The question
Maintain a real-time view of cardiometabolic pipeline read-outs and probability-adjusted threat scoring against the duopoly.
What we did
Annual retainer covering: monthly pipeline matrix; ADA / EASD / AHA conference previews; 24-hour read-out reaction notes; quarterly threat ranking review.
The outcome
Three position-sizing decisions in the past 12 months attributed to Avenbuan read-out reaction notes. Retainer renewed for a second year.
Case 06 · Bespoke research
Investment-banking team — IPO pitch evidence pack
The question
Build the evidence pack underpinning a sector positioning section for a cardiometabolic biotech IPO pitch.
What we did
Two-week analyst sprint. Source extraction across SEC filings, FDA briefing documents, EvaluatePharma comparables, and NEJM publications. Delivered a 30-page evidence pack plus a 6-slide pitch insert.
The outcome
Materials used in two follow-on management roadshow meetings. Sponsor invited us back for the diligence phase.